Company intelligence / Profile preview

LabTAU

Taipei/Shilin District, Taipei City, Taiwanlabtau.univ-lyon1.fr ↗

Ownership: Private
Development stage: Commercial

Overview

LabTurbo develops automated molecular diagnostic platforms for high-throughput nucleic acid extraction and multiplex PCR-based genetic testing. Their systems are used in clinical diagnostics for infectious disease detection, cancer mutation analysis, and newborn screening. The company operates CAP-certified CLIA laboratories in the US and Taiwan. They have established partnerships to expand into precision medicine applications such as MassARRAY-based cancer hotspot testing. Their products are ISO13485/GMP certified.

Therapeutic areas: OncologyRare DiseasesInfectious Diseases
Modalities: DeviceReagentsDiagnostic technology
Industry: Molecular Diagnostics

Partnerships

FENG CHI BIOTECH CORP.

Beyond the preview

Go deeper on LabTAU.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LabTAU.

Explore the full profile